Cyclopharm Limited (ASX:CYC – Get Rating) insider David Heaney acquired 10,000 shares of the firm’s stock in a transaction on Tuesday, June 14th. The shares were bought at an average cost of A$1.15 ($0.80) per share, with a total value of A$11,450.00 ($7,951.39).

David Heaney also recently made the following trade(s):

• On Thursday, May 19th, David Heaney purchased 5,500 shares of Cyclopharm stock. The stock was acquired at an average cost of A$1.36 ($0.94) per share, with a total value of A$7,480.00 ($5,194.44).

The company has a quick ratio of 5.04, a current ratio of 5.83 and a debt-to-equity ratio of 10.47.

The firm also recently declared a Final dividend, which was paid on Monday, April 11th. Stockholders of record on Monday, April 11th were issued a $0.005 dividend. The ex-dividend date of this dividend was Sunday, April 3rd. This represents a dividend yield of 0.32%. Cyclopharm’s dividend payout ratio is currently -17.86%.

Cyclopharm Company Profile (Get Rating)

Cyclopharm Limited manufacture and sells medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, and internationally. It operates through Technegas and Molecular Imaging segments. The Technegas segment offers diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism.

See Also

Receive News & Ratings for Cyclopharm Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Cyclopharm and related companies with MarketBeat.com’s FREE daily email newsletter.